A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Interval of at least 12 weeks from completion of adjuvant radiotherapy for gliomas to study entry
* Karnofsky Performance Status of \>/= 70 at screening
* Confirmed measurable disease per RANO
* Adequate hematologic and organ function

Patients enrolled in Stage 1:

* Histologically documented recurrent or progressive high-grade gliomas (WHO Grade III-IV)
* Prior treatment with at least one regimen for gliomas (radiotherapy with or without chemotherapy for Grade III gliomas and radiotherapy with chemotherapy for Grade IV gliomas) and/or not considered to be a candidate for regimens known to provide clinical benefit

Patients enrolled in Stage 2:

* Histologically documented recurrent or progressive glioblastoma (WHO Grade IV gliomas)
* Prior treatment with one or two regimens for glioblastoma (with the initial regimen consisting of radiotherapy with chemotherapy)

Exclusion Criteria:

* Treatment with anti-tumor therapy (approved or experimental) within 4 weeks prior to initiation of study drug
* Requirement for anticoagulants such as warfarin or any other warfarin-derivative anticoagulants; low-molecular-weight heparin is permitted
* Any contraindication to MRI examination
* Evidence of Grade \>/= 1 intracranial hemorrhage
* Active congestive heart failure or ventricular arrhythmia requiring medication
* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse or cirrhosis
* Unresolved toxicity from prior therapy with the exception of lymphopenia (for patients with prior temozolomide) and alopecia
* Pregnant or lactating women